Epistatic interactions between mutations of TACI (TNFRSF13B) and TCF3 result in a severe primary immunodeficiency disorder and systemic lupus erythematosus

Clinical and Translational Immunology

Volumn 6, Issue 10, 2017, Pages

  Ameratunga, Rohan ^a   Koopmans, Wikke ^a   Woon, See Tarn ^a   Leung, Euphemia ^b   Lehnert, Klaus ^c   Slade, Charlotte A ^d,e,f   Tempany, Jessica C ^d,e   Enders, Anselm ^g   Steele, Richard ^a   Browett, Peter ^h,i   Hodgkin, Philip D ^d,e   Bryant, Vanessa L ^d,e,f  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g Australian National University   (Australia)

^h AUCKLAND CITY HOSPITAL   (New Zealand)

ⁱ UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85047015687     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/CTI.2017.41     Document Type: Article

References (42)

1. Abbott JK, Gelfand EW. Common variable immunodeficiency: diagnosis, management, and treatment. Immunol Allergy Clin North Am 2015; 35: 637–658.
2. Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol 2013; 174: 203–211.
3. Grimbacher B, Hutloff A, Schlesier M, Glocker E, Warnatz K, Drager R et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 2003; 4: 261–268.
4. van Zelm MC, Reisli I, van der Burg M, Castano D, van Noesel CJ, van Tol MJ et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006; 354: 1901–1912.
5. van Zelm MC, Smet J, Adams B, Mascart F, Schandene L, Janssen F et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest 2010; 120: 1265–1274.
6. Fliegauf M, Bryant VL, Frede N, Slade C, Woon S-T, Lehnert K et al. Haploinsufficiency of the NF-κB1 subunit p50 in common variable immunodeficiency. Am J Hum Genet 2015; 97: 389–403.
7. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency 2015. J Clin Immunol. 2015; 35: 696–726.
8. Ameratunga R, Woon ST, Neas K, Love DR. The clinical utility of molecular diagnostic testing for primary immune deficiency disorders: a case based review. Allergy Asthma Clin Immunol 2010; 6: 12.
9. Ameratunga R, Woon ST, Brewerton M, Koopmans W, Jordan A, Brothers S et al. Primary immune deficiency disorders in the South Pacific: the clinical utility of a customized genetic testing program in New Zealand. Ann NY Acad Sci 2011; 1238: 53–64.
10. Pan-Hammarstrom Q, Salzer U, Du L, Bjorkander J, Cunningham-Rundles C, Nelson DL et al. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet 2007; 39: 429–430.
11. Poodt AE, Driessen GJ, de Klein A, van Dongen JJ, van der Burg M, de Vries E. TACI mutations and disease susceptibility in patients with common variable immunodeficiency. Clin Exp Immunol 2009; 156: 35–39.
12. Koopmans W, Woon ST, Brooks AE, Dunbar PR, Browett P, Ameratunga R. Clinical variability of family members with the C104R mutation in transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). J Clin Immunol 2013; 33: 68–73.
13. Bateson L. Discussion on the influence of heredity on disease, with special reference to tuberculosis, cancer, and diseases of the nervous system: introductory address. Proc R Soc Med 1909; 2(Gen Rep): 22–30.
14. Hill WG, Goddard ME, Visscher PM. Data and theory point to mainly additive genetic variance for complex traits. PLoS Genet 2008; 4: e1000008.
15. Mackay TF, Moore JH. Why epistasis is important for tackling complex human disease genetics. Genome Med 2014; 6: 124.
16. Schaffer AA. Digenic inheritance in medical genetics. J Med Genet 2013; 50: 641–652.
17. Ameratunga R, Brewerton M, Slade C, Jordan A, Gillis D, Steele R et al. Comparison of diagnostic criteria for Common Variable Immunodeficiency Disorder. Front Immunol 2014; 5: 415.
18. Ameratunga R, Storey P, Barker R, Jordan A, Koopmans W, Woon ST. Application of diagnostic and treatment criteria for common variable immunodeficiency disorder. Expert Rev Clin Immunol 2015; 12: 257–266.
19. Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for CVID. Expert Rev Clin Immunol 2014; 10: 183–186.
20. Agarwal S, Cunningham-Rundles C. Treatment of hypogammaglobulinemia in adults: a scoring system to guide decisions on immunoglobulin replacement. J Allergy Clin Immunol 2013; 131: 1699–1701.
21. Denis CM, Langelaan DN, Kirlin AC, Chitayat S, Munro K, Spencer HL et al. Functional redundancy between the transcriptional activation domains of E2A is mediated by binding to the KIX domain of CBP/p300. Nucleic Acids Res 2014; 42: 7370–7382.
22. Bain G, Maandag EC, Izon DJ, Amsen D, Kruisbeek AM, Weintraub BC et al. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell 1994; 79: 885–892.
23. Quong MW, Harris DP, Swain SL, Murre C. E2A activity is induced during B-cell activation to promote immunoglobulin class switch recombination. EMBO J 1999; 18: 6307–6318.
24. Mai T, Pone EJ, Li G, Lam TS, Moehlman J, Xu Z et al. Induction of activation-induced cytidine deaminase-targeting adaptor 14-3-3 gamma is mediated by NF-kappaBdependent recruitment of CFP1 to the 5'-CpG-3'-rich 14-3-3 gamma promoter and is sustained by E2A. J immunol 2013; 191: 1895–1906.
25. He B, Santamaria R, Xu W, Cols M, Chen K, Puga I et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 2010; 11: 836–845.
26. Bacchelli C, Buckland KF, Buckridge S, Salzer U, Schneider P, Thrasher AJ et al. The C76R transmembrane activator and calcium modulator cyclophilin ligand interactor mutation disrupts antibody production and B-cell homeostasis in heterozygous and homozygous mice. J Allergy Clin Immunol 2011; 127: 1253–1259 e1213.
27. Bryant VL, Ma CS, Avery DT, Li Y, Good KL, Corcoran LM et al. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J immunol 2007; 179: 8180–8190.
28. Avery DT, Bryant VL, Ma CS, de Waal Malefyt R, Tangye SG. IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J Immunol 2008; 181: 1767–1779.
29. Tangye SG, Hodgkin PD. Divide and conquer: the importance of cell division in regulating B-cell responses. Immunology 2004; 112: 509–520.
30. Hodgkin PD, Lee JH, Lyons AB. B cell differentiation and isotype switching is related to division cycle number. J Exp Med 1996; 184: 277–281.
31. Moore JH. A global view of epistasis. Nat Genet 2005; 37: 13–14.
32. Hall MD, Ebert D. The genetics of infectious disease susceptibility: has the evidence for epistasis been overestimated? BMC Biol 2013; 11: 79.
33. Massaad MJ, Zhou J, Tsuchimoto D, Chou J, Jabara H, Janssen E et al. Deficiency of base excision repair enzyme NEIL3 drives increased predisposition to autoimmunity. J Clin Invest 2016; 126: 4219–4236.
34. Lopez-Herrera G, Tampella G, Pan-Hammarstrom Q, Herholz P, Trujillo-Vargas CM, Phadwal K et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet 2012; 90: 986–1001.
35. Boisson B, Wang YD, Bosompem A, Ma CS, Lim A, Kochetkov T et al. A recurrent dominant negative E47 mutation causes agammaglobuline) B cells. J clin invest 2013; 123: 4781–4785.
36. van Schouwenburg PA, Davenport EE, Kienzler AK, Marwah I, Wright B, Lucas M et al. Application of whole genome and RNA sequencing to investigate the genomic landscape of common variable immunodeficiency disorders. Clin Immunol 2015; 160: 301–314.
37. Rodriguez-Cortez VC, Del Pino-Molina L, Rodriguez-Ubreva J, Ciudad L, Gomez-Cabrero D, Company C et al. Monozygotic twins discordant for common variable immunodeficiency reveal impaired DNA demethylation during naive-to-memory B-cell transition. Nat Commun 2015; 6: 7335.
38. Ahsberg J, Ungerback J, Strid T, Welinder E, Stjernberg J, Larsson M et al. Early B-cell factor 1 regulates the expansion of B-cell progenitors in a dose-dependent manner. J Biol Chem 2013; 288: 33449–33461.
39. Tallmadge RL, Such KA, Miller KC, Matychak MB, Felippe MJ. Expression of essential B cell development genes in horses with common variable immunodeficiency. Mol Immunol 2012; 51: 169–176.
40. Garibyan L, Lobito AA, Siegel RM, Call ME, Wucherpfennig KW, Geha RS. Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID). J Clin Invest 2007; 117: 1550–1557.
41. Salzer U, Bacchelli C, Buckridge S, Pan-Hammarstrom Q, Jennings S, Lougaris V et al. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood 2009; 113: 1967–1976.
42. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T et al. Analysis of protein-coding genetic variation in 60 706 humans. Nature 2016; 536: 285–291.